Medical technology company Signifier Medical Technologies revealed on Friday the completion of an oversubscribed Series B funding round led by The Pritzker Organization and includes participation from new investors as well as existing investors.
Following this round, Signifier Medical Technologies has raised a total in excess of USD13m since its founding in 2015.
The new funds will be used by Signifier to accelerate the rigorous data generation in on-going clinical trials of its innovative 'Snoozeal' neurostimulation device to address snoring and mild obstructive sleep apnoea (OSA) in the University College London, University of California - San Diego and New York Presbyterian – Cornell University; complete US FDA de novo filing approval process; and expand its product range, analytics capabilities and the team in key geographies.
Under the terms of the Series B round, Steffen Kastner, former managing director of Goldman Sachs, and Robert Sullivan, former CEO, COO and founder of Capital Holdings and the current regional president of Fifth Third Bancorp, will join the chairman Kieran Gallahue on Signifier's board.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML